Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: Spain,Czech Republic,United Kingdom,Belgium,Sweden,Austria,Germany,Italy,Serbia,Poland
Trial Manager
Update Il y a 5 ans
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
To assess the efficacy of two different treatment regimens of etanercept in psoriasis subjects with psoriatic arthritis with respect to both the skin and joint manifestations.
Country
Argentina
,
Australia
,
Austria
,
Belgium
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Hungary
,
Italy
,
Korea, Republic of
,
Mexico
,
Netherlands
,
Poland
,
Portugal
,
Saudi Arabia
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Taiwan, Province of China
,
Turkey
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Country
Australia
,
Austria
,
Belgium
,
Bulgaria
,
Canada
,
Czech Republic
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Patients will be randomised to receive either placebo or the study drug for a period of 30 weeks, in addition to their standard Parkinsonian medications. During the first 8 weeks, the patient's levodopa doses may be adjusted if necessary by the investigator. For the remainder of the 22 weeks, all medications should be kept stable. Patients will be required to attend the clinic twice during the screening period and then a further 8 times during the treatment period. They will be required to complete home diaries where they will record their motor function. In addition, their doctor will assess their Parkinson's disease during the clinic visits. There will also be blood draws for safety and pharmacokinetic and pharmacogenomics evaluation. Following the treatment and assessment period, they will return to the clinic one month later for follow up.
Country
Austria
,
Belgium
,
Czech Republic
,
Estonia
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Lithuania
,
Poland
,
Portugal
,
Serbia
,
South Africa
,
Spain
,
Sweden
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
1